Scrip
Flat first quarter for Eisai
03 August 2009
Ian Haydock
Please Login to read the full article.
03 August 2009
Ian Haydock
ian.haydock@informa.com
Despite a rise in global sales of the Alzheimer's disease therapy Aricept (donepezil), Eisai's net sales in the first quarter to June 30th slipped by around 1% to ¥194.7 billion ($2.05 billion), hit by currency effects and weakness for its other mainstay product, Aciphex/Pariet (rabeprazole).
Sales...
Please Login to read the full article.
RELATED CONTENT
ANALYSIS
- Mind over matter - partnerships: CNS deals signed over the past five years
- Mind over matter - CNS: from Parkinson's to pain
COMMENT
Other Informa Comment
